Kata Judit Szántó (Kata Szántó)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 17

Top Topics

Ulcerative Colitis

Patients With Inflammatory Bowel Disease

Cross Sectional

Top Venues

Therapeutic advances in gastroenterology

Expert opinion on biological therapy

Expert opinion on drug safety

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Tamás Resál, Katalin Mangó, Péter Bacsur, Kata Judit Szántó, Daniella Pigniczki, Csilla Keresztes, Mariann Rutka, Anita Bálint, Ágnes Milassin, Renáta Bor, Anna Fábián, Zoltán Szepes, Klaudia Farkas, Katalin Monostory, Tamás Molnár
Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone. Expert opinion on drug safety (2023)
Péter Bacsur, Mariann Rutka, András Asbóth, Tamás Resál, Kata Judit Szántó, Boldizsár Jójárt, Anita Bálint, Eszter Ari, Walliyulahi Ajibola, Bálint Kintses, Tamás Fehér, Daniella Pigniczki, Renáta Bor, Anna Fábián, József Maléth, Zoltán Szepes, Klaudia Farkas, Tamás Molnár
Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls. Therapeutic advances in gastroenterology 16 (2023)
Tamás Resál, Katalin Mangó, Péter Bacsur, Kata Judit Szántó, Daniella Pigniczki, Csilla Keresztes, Mariann Rutka, Anita Bálint, Ágnes Milassin, Renáta Bor, Anna Fábián, Zoltán Szepes, Klaudia Farkas, Katalin Monostory, Tamás Molnár
Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone. Expert opinion on drug safety (2023)
Tamás Resál, Péter Bacsur, Miklós Horváth, Kata Judit Szántó, Mariann Rutka, Anita Bálint, Anna Fábián, Renáta Bor, Zoltán Szepes, János Fekete, Klaudia Farkas, Pál Miheller, Tamás Molnár
Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination. Therapeutic advances in gastroenterology 16 (2023)
Boldizsár Jójárt, Tamás Resál, Diána Kata, Tünde Molnár, Péter Bacsur, Viktória Szabó, Árpád Varga, Kata Judit Szántó, Petra Pallagi, Imre Földesi, Tamás Molnár, József Maléth, Klaudia Farkas
Plasminogen activator inhibitor 1 is a novel faecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases. Journal of Crohn's & colitis (2023)
Péter Bacsur, Mária Matuz, Tamás Resál, Pál Miheller, Tamás Szamosi, Eszter Schäfer, Patricia Sarlos, Ákos Iliás, Kata Judit Szántó, Mariann Rutka, Anita Bálint, Ágnes Csontos, Anna Fábián, Renáta Bor, Zoltán Szepes, Tamás Molnár, Klaudia Farkas
Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn's disease: results from a multicentre cohort study. Therapeutic advances in gastroenterology 15 (2022)
Péter Bacsur, Mária Matuz, Tamás Resál, Pál Miheller, Tamás Szamosi, Eszter Schäfer, Patricia Sarlos, Ákos Iliás, Kata Judit Szántó, Mariann Rutka, Anita Bálint, Ágnes Csontos, Anna Fábián, Renáta Bor, Zoltán Szepes, Tamás Molnár, Klaudia Farkas
Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn's disease: results from a multicentre cohort study. Therapeutic advances in gastroenterology 15 (2022)
Tamás Resál, Renáta Bor, Kata Judit Szántó, Anna Fábián, Mariann Rutka, Marco Sacco, Davide Guiseppe Ribaldone, Pauliina Molander, Stephane Nancey, Uri Kopylov, Stephan Vavricka, David Drobne, Milan Lukas, Klaudia Farkas, Zoltán Szepes, Tamás Molnár
Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey. Therapeutic advances in gastroenterology 14 (2021)
Kata Judit Szántó, Tamara Madácsy, Diána Kata, Tamás Ferenci, Mariann Rutka, Anita Bálint, Renáta Bor, Anna Fábián, Ágnes Csontos, Boldizsár Jójárt, Zoltán Szepes, Ferenc Nagy, Tamás Molnár, Imre Földesi, József Maléth, Klaudia Farkas
Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α antagonists. Expert opinion on biological therapy 21 (4) (2021)
Kata Judit Szántó, Tamás Balázs, Dóra Mihonné Schrempf, Klaudia Farkas, Tamás Molnár
Does inflammatory bowel disease have different characteristics according to stage of adolescence? Therapeutic advances in gastroenterology 14 (2021)
Péter Kunovszki, Kata Judit Szántó, Judit Gimesi-Országh, Péter Takács, Andras Borsi, Anita Bálint, Klaudia Farkas, Ágnes Csontos, Péter L Lakatos, Tamás Szamosi, Tamás Molnár
Epidemiological data and utilization patterns of anti-TNF alpha therapy in the Hungarian ulcerative colitis population between 2012-2016. Expert opinion on biological therapy 20 (4) (2020)
Péter Kunovszki, Ágnes Milassin, Judit Gimesi-Országh, Péter Takács, Kata Judit Szántó, Anita Bálint, Klaudia Farkas, András Borsi, Péter L Lakatos, Tamás Szamosi, Tamás Molnár
Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary - a population-based study. PloS one 15 (5) (2020)
Renáta Bor, Béla Vasas, Anna Fábián, Mónika Szücs, Árpád Füredi, László Czakó, Mariann Rutka, Klaudia Farkas, Tamás Molnár, Ágnes Csontos, Anita Bálint, Kata Judit Szántó, Sándor Hamar, László Kaizer, László Tiszlavicz, Zoltán Szepes
Slow-pull technique yields better quality smears: prospective comparison of slow-pull and standard suction techniques of endoscopic ultrasound-guided fine-needle aspiration. Scandinavian journal of gastroenterology 55 (11) (2020)
Anett Sánta, Kata Judit Szántó, Patrícia Sarlós, Pál Miheller, Klaudia Farkas, Tamás Molnár
Letter: suicide risk among adult inflammatory bowel disease patients. Alimentary pharmacology & therapeutics 51 (11) (2020)
Tamás Resál, Daniella Pigniczki, Kata Judit Szántó, Mariann Rutka, Klaudia Farkas, Tamas Molnar
Letter: ciclosporin and vedolizumab for steroid-refractory ulcerative colitis. Alimentary pharmacology & therapeutics 52 (3) (2020)
Renáta Bor, Anna Fábián, Mária Matuz, Zoltán Szepes, Klaudia Farkas, Pál Miheller, Tamás Szamosi, Áron Vincze, Mariann Rutka, Kata Judit Szántó, Anita Bálint, Ferenc Nagy, Ágnes Csontos, Tibor Tóth, Ferenc Zsigmond, Judit Bajor, Katalin Müllner, Lilla Lakner, Mária Papp, Ágnes Salamon, Gábor Horváth, Krisztina Sarang, Eszter Schäfer, Patrícia Sarlós, Károly Palatka, Tamás Molnár
Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study. Expert opinion on biological therapy 20 (2) (2019)
Anita Bálint, Mariann Rutka, Martin Kolar, Dana Duricova, Veronika Hruba, Katarina Mitrova, Karin Malickova, Milan Lukas, Zoltán Szepes, Ferenc Nagy, Károly Palatka, Szilvia Lovas, Zsuzsanna Végh, Zsuzsanna Kürti, Ágnes Csontos, Pál Miheller, Tibor Nyári, Renáta Bor, Anna Fábián, Kata Judit Szántó, Péter L Lakatos, Tamás Molnár, Klaudia Farkas
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort. Expert opinion on biological therapy 18 (11) (2018)